ASRT Earnings

ASRT reported its FY2025Q3 earnings on 2025-11-10, showcasing a revenue of 49.00M against an estimate of 27.00M, resulting in a 83.05% surprise. The EPS was 0.18, surpassing the expected -0.08 by 325% . The stock experienced a 14.89% price change on the earnings day and a -1.25% change over the next five days, reflecting market reactions to the results.

Following ASRT's FY2025Q3 earnings announcement on 2025-11-10, the stock price moved by 14.89% on the day of the release. Over the subsequent five days, it saw a -1.25% change. Historically, ASRT's stock price tends to shift by an average of +0.46% in the 10 days leading up to earnings and -7.19% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ASRT’s annual revenue to reach 6.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.39% and EPS estimates Revise Downward by -72.54% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ASRT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.39%, while EPS estimates moved Revise Downward by -72.54% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ASRT's stock price typically moves by +0.46% in the 10 days before its earnings and -7.19% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 6.00M.

Despite strong financial results driven by Rolvedon sales, concerns about dependency on Rolvedon, generic competition for Indocin, and temporary cash reserve declines temper optimism. The Q&A highlighted management's vague responses on strategic priorities and reimbursement strategies, adding uncertainty. Positive elements include increased EBITDA, net income, and a stable debt position. The decommercialization of Otrexup and its impact on revenue and costs also weigh in. Overall, the stock is likely to remain stable as positive financial performance is offset by uncertainties and risks.